Format

Send to

Choose Destination
J Am Coll Cardiol. 2013 Jun 18;61(24):2417-2427. doi: 10.1016/j.jacc.2013.03.034. Epub 2013 Apr 10.

Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.

Author information

1
Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, California. Electronic address: mddake@stanford.edu.
2
Center for Critical Limb Care, Riverside Methodist Hospital, Columbus, Ohio.
3
The Vascular Center, Massachusetts General Hospital, Boston, Massachusetts.
4
Department of Surgery, Jikei University Hospital, Tokyo, Japan.
5
Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, California.
6
Department of Radiology, OSF St. Francis Medical Center, Peoria, Illinois.
7
MED Institute, Inc., West Lafayette, Indiana.
8
Department of Radiology, Klinikum Rosenheim, Rosenheim, Germany.
9
Department of Cardiology, Center for Vascular Medicine, Park Hospital, Leipzig, Germany.
10
Department of Angiology, Herz Zentrum, Bad Krozingen, Germany.

Erratum in

  • J Am Coll Cardiol. 2013 Aug 13;62(7):666.

Abstract

OBJECTIVES:

A prospective, multinational randomized controlled trial (RCT) and a complementary single-arm study evaluated the 2-year safety and effectiveness of a paclitaxel-coated drug-eluting stent (DES) in patients with superficial femoral artery lesions. The RCT compared the DES with percutaneous transluminal angioplasty (PTA) and provisional bare-metal stent (BMS) placement.

BACKGROUND:

Local drug delivery for superficial femoral artery lesions has been investigated with the intent of limiting restenosis similarly to DES for the coronary arteries. One-year outcomes of DES in the superficial femoral artery are promising, but longer-term benefits have not been established.

METHODS:

In the RCT, patients were randomly assigned to primary DES implantation (n = 236) or PTA (n = 238). Acute PTA failure occurred in 120 patients, who underwent secondary randomization to DES (n = 61) or BMS (n = 59) placement. The single-arm study enrolled 787 patients with DES treatment.

RESULTS:

Compared with the control group, the primary DES group demonstrated significantly superior 2-year event-free survival (86.6% vs. 77.9%, p = 0.02) and primary patency (74.8% vs. 26.5%, p < 0.01). In addition, the provisional DES group exhibited superior 2-year primary patency compared with the provisional BMS group (83.4% vs. 64.1%, p < 0.01) and achieved higher sustained clinical benefit (83.9% vs. 68.4%, p = 0.05). Two-year freedom from target lesion revascularization with primary DES placement was 80.5% in the single-arm study and 86.6% in the RCT.

CONCLUSIONS:

Two-year outcomes with the paclitaxel-eluting stent support its sustained safety and effectiveness in patients with femoropopliteal artery disease, including the long-term superiority of the DES to PTA and to provisional BMS placement. (Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery; NCT00120406; Zilver(®) PTX™ Global Registry; NCT01094678).

PMID:
23583245
DOI:
10.1016/j.jacc.2013.03.034
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center